PDF(Pubmed)
Abstract：
BN-202M is derived from humans and consists of two strains, Lacticaseibacillus paracasei BEPC22 and Lactiplantibacillus plantarum BELP53. Body fat reduction effect and safety of BN-202M were assessed in overweight participants. A total of 150 participants were randomly assigned to the BN-202M and placebo groups at a 1:1 ratio. Dual-energy X-ray absorptiometry was used to objectively measure body fat. After 12 weeks of oral administration, the body fat percentage (-0.10 ± 1.32% vs. 0.48 ± 1.10%; p = 0.009) and body fat mass (-0.24 ± 1.19 kg vs. 0.23 ± 1.05 kg; p = 0.023) of the BN-202M group decreased significantly compared to those of the placebo group. The body weight (-0.58 kg, p = 0.004) and body mass index (BMI; -0.23, p = 0.003) was found to decrease significantly at 12 weeks in the BN-202M group, but not in the placebo group. Metabolome analysis revealed that β-alanine, 3-aminoisobutyric acid, glutamic acid, and octopamine decreased in the weight-decreased BN-202M post-intake group. In the gut microbiota analysis, Akkermansia showed a statistically significant increase in the BN-202M group post-intake compared to the placebo group. No serious adverse events were observed in either group. These results suggest that BN-202M is safe and effective for reducing body fat and weight.
摘要：
BN-202M来自人类，由两个菌株组成，副干酪乳杆菌BEPC22和植物乳杆菌BELP53。在超重参与者中评估BN-202M的体脂减少效果和安全性。共有150名参与者以1:1的比例随机分配到BN-202M和安慰剂组。采用双能X线吸收法客观测量体脂。口服12周后，体脂百分比(-0.10±1.32%vs.0.48±1.10％；p=0.009）和体脂质量（-0.24±1.19kgvs.与安慰剂组相比，BN-202M组的0.23±1.05kg；p=0.023）显着降低。体重（-0.58公斤，p=0.004）和体重指数（BMI;-0.23，p=0.003）在BN-202M组中在12周时显着降低，但安慰剂组没有。代谢组分析显示，β-丙氨酸，3-氨基异丁酸,谷氨酸，在摄入后体重减轻的BN-202M组中，章鱼胺降低。在肠道微生物群分析中，与安慰剂组相比，摄入后BN-202M组的Akkermansia显示出统计学上的显着增加。两组均未发生严重不良事件。这些结果表明BN-202M对于减少体脂和体重是安全有效的。
